CompletedNot Applicable

Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

Egypt40 participantsStarted 2021-08-01

Plain-language summary

Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid patients, to participate in understanding of real hidden pathophysiology of COVID-19.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Severe ARDS: PaO2/FiO2 \<200, resistant hypoxemia and tachypnoea (RR \> 40 breath/minute) * Not relieved by high frequency nasal canula or CPAP. * Need for invasive mechanical ventilation (uncooperative) Exclusion Criteria: * Patient relatives' refusal * Not mechanically ventilated. * Combination of female, corticosteroids administration and vecuronium muscle relaxant. * Neuromuscular diseases (especially demyelinating diseases).

What they're measuring

PaO2/FiO2

Timeframe: 48 hours

Trial details

NCT IDNCT04922814

SponsorAssiut University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03-01

View on ClinicalTrials.gov More COVID-19 Acute Respiratory Distress Syndrome trials